This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Boston Scientific Launches Trial To Evaluate Neurostimulation For Treatment Of Chronic Migraine

NATICK, Mass., July 19, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has launched a clinical trial to determine whether occipital nerve stimulation (ONS) using the Precision™ System can safely and effectively treat chronic migraine when used in conjunction with anti-migraine medications.  The OPTIMISE trial -- a multi-center, randomized, placebo-controlled study -- is expected to be used to support various regulatory approvals of this novel therapy for chronic migraine.

The first patient to undergo this procedure was treated at Mercy Hospital in Springfield, Mo., by Benjamin Lampert, M.D., using the Boston Scientific Precision System, which features multiple independent current control (MICC) technology.  With ONS, a small programmable implanted device sends electrical impulses to the greater occipital nerve, which runs from the top of the spinal cord to the base of the scalp. Initial studies suggest that by stimulating the occipital nerve, it may be possible to mask the pain associated with chronic migraine 1-3

"By directly targeting the occipital nerve with neurostimulation, we are potentially able to offer patients an effective and relatively low-risk therapy," said Richard Lipton, M.D., professor of neurology and director of the Montefiore Headache Center at Albert Einstein College of Medicine in New York and principal investigator for the study.  "I am excited to further evaluate the clinical utility of the Boston Scientific Precision System with MICC technology as a treatment for chronic migraine."

Migraine is a neurological disorder affecting one in 10 adults worldwide.  Sufferers have headaches that last more than four hours a day with some adults experiencing headaches 15 or more days per month.  Migraine is considered by the World Health Organization (WHO) to be one of the top disabling conditions worldwide.  Despite the available treatment options, many migraine patients are unable to find relief. 

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,888.35 +168.43 0.95%
S&P 500 2,102.63 +22.22 1.07%
NASDAQ 5,156.3060 +47.64 0.93%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs